DEF: Stoke Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Stoke Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 3, 2025, outlining proposals for director elections, auditor ratification, and executive compensation.

Summary

• Stoke Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 3, 2025, at 9:00 a.m. Eastern Time.
• Stockholders of record as of April 7, 2025, are entitled to vote.
• The meeting will include the election of Edward M. Kaye, Seth L. Harrison, and Arthur O. Tzianabos as Class III directors, each for a term expiring in 2028.
• Stockholders will also vote to ratify the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• An advisory vote will be held to approve the compensation of the company's named executive officers.
• Additionally, stockholders will indicate their preferred frequency (every one, two, or three years) for future advisory votes on executive compensation.
• The Board of Directors recommends voting for the election of the director nominees, for the ratification of KPMG LLP, for the approval of executive compensation, and for holding the advisory vote every one year.
• The company is furnishing proxy materials to stockholders primarily via the Internet, with a Notice of Internet Availability mailed around April 22, 2025.
• As of April 7, 2025, there were 54,596,924 shares of common stock outstanding and entitled to vote.
• The Board of Directors has determined that Jennifer C. Burstein, Seth L. Harrison, Adrian R. Krainer, Arthur A. Levin, Garry E. Menzel, and Julie Anne Smith are independent directors.
• The company's non-employee director compensation program includes an annual cash retainer of $40,000, with additional payments for committee chairs and members.
• Each new non-employee director will receive an initial option grant with a fair market value of approximately $448,000, and continuing directors will receive an annual option grant with a fair market value of approximately $224,000.
• The company's executive officers as of April 7, 2025, include Arthur O. Tzianabos (Interim Executive Chair), Ian F. Smith (Interim Chief Executive Officer), Thomas E. Leggett (Chief Financial Officer), Barry S. Ticho (Chief Medical Officer), and Jonathan Allan (General Counsel and Corporate Secretary).

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The positive aspects include the company's commitment to corporate governance and employee benefits, while potential risks are acknowledged. Overall, the sentiment is moderately positive.

Positives

• The company is committed to good corporate governance practices, including a Code of Conduct and Corporate Governance Guidelines.
• The Board of Directors has a compensation recovery policy (Clawback Policy) in place.
• The company is committed to investing in its employees by offering comprehensive and competitive benefits.
• The company has a diverse workforce, with approximately 57% of employees being female and over 36% self-identifying as racially or ethnically diverse.
• The company's Audit Committee pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm.

Risks

• The company's business increasingly depends on the efficient and uninterrupted operation of its information technology systems and those of its third-party contract research organizations, contract manufacturing organizations, or other vendors, contractors or consultants.
• The company recognizes the critical importance of maintaining the trust and confidence of all of its stakeholders.

Future Outlook

The company is seeking stockholder approval for key proposals to ensure continued governance and strategic direction.

Management Comments

• Ian F. Smith, Interim Chief Executive Officer: 'Your vote is important. Whether or not you plan to attend the virtual Annual Meeting, please vote on the Internet or by telephone, or request, sign and return a proxy card to ensure that your shares are represented at the meeting.'

Industry Context

The document reflects standard corporate governance practices for publicly traded biotechnology companies, including director independence, committee structures, and executive compensation policies. The use of a virtual meeting format is increasingly common to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The peer group used for compensation benchmarking includes companies like 4D Molecular Therapeutics, Generation Bio, and Editas Medicine, reflecting a focus on gene and cell editing companies in Phase 1-2 clinical trials.
• The non-employee director compensation program is designed to align with the 65th percentile of the peer group, indicating a competitive approach to attracting and retaining board members.
• The company's approach to cybersecurity risk oversight aligns with recognized industry best practices, including cross-functional collaboration and regular reporting to the Board and Audit Committee.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's governance and strategic direction.
• Employees are impacted by the company's commitment to competitive benefits and a diverse and inclusive workplace.
• The company's cybersecurity policies aim to protect the interests of all stakeholders by preserving the confidentiality, integrity, and availability of information.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on June 3, 2025, to address the proposals.
• The Board of Directors and management will consider the results of the advisory votes on executive compensation in future decisions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, KPMG, Corporate Governance, Audit Committee, Compensation Committee, Stoke Therapeutics